Genomic profiling of collecting duct renal carcinoma

Chintala, Sreenivasulu; Пили, Роберто

doi:10.18632/aging.101109

Cited by 4 publications

(5 citation statements)

References 8 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SLC7A11 (xCT) is an anionic amino acid transporter that is highly specific for the amino acids cysteine and glutamate [30]. Increased expression of SLC7A11 at the RNA and protein levels in CDCs has been shown previously [8,11].…”

Section: Discussionmentioning

confidence: 99%

“…As previously described, many SLC genes in CDC are dysregulated in comparison to normal tissue samples [8,11]. Therefore, we decided to investigate the expression of SLC genes in more detail.…”

Section: Solute Carrier Genesmentioning

confidence: 99%

“…However, there are treatment suggestions for metastatic CDC, i.e., first-line therapy with a combination of chemotherapy (gemcitabine) plus cisplatin/carboplatin, and second-line therapy as a targeted therapy [2,3]. Suggestions to treat CDC patients with drugs that target solute carriers, such as SLC7A11 or SLC6A7, have been made previously [11]. However, further molecular characterization of CDC is needed to better understand its tumor biology and to identify potential therapeutic targets.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

RNA Sequencing of Collecting Duct Renal Cell Carcinoma Suggests an Interaction between miRNA and Target Genes and a Predominance of Deregulated Solute Carrier Genes

Wach

Täubert

Weigelt

et al. 2019

Cancers

View full text Add to dashboard Cite

Collecting duct carcinoma (CDC) is a rare renal cell carcinoma subtype with a very poor prognosis. There have been only a few studies on gene expression analysis in CDCs. We compared the gene expression profiles of two CDC cases with those of eight normal tissues of renal cell carcinoma patients. At a threshold of |log2fold-change| ≥1, 3349 genes were upregulated and 1947 genes were downregulated in CDCs compared to the normal samples. Pathway analysis of the deregulated genes revealed that cancer pathways and cell cycle pathways were most prominent in CDCs. The most upregulated gene was keratin 17, and the most downregulated gene was cubilin. Among the most downregulated genes were four solute carrier genes (SLC3A1, SLC9A3, SLC26A7, and SLC47A1). The strongest negative correlations between miRNAs and mRNAs were found between the downregulated miR-374b-5p and its upregulated target genes HIST1H3B, HK2, and SLC7A11 and between upregulated miR-26b-5p and its downregulated target genes PPARGC1A, ALDH6A1, and MARC2. An upregulation of HK2 and a downregulation of PPARGC1A, ALDH6A1, and MARC2 were observed at the protein level. Survival analysis of the cancer genome atlas (TCGA) dataset showed for the first time that low gene expression of MARC2, cubilin, and SLC47A1 and high gene expression of KRT17 are associated with poor overall survival in clear cell renal cell carcinoma patients. Altogether, we identified dysregulated protein-coding genes, potential miRNA-target interactions, and prognostic markers that could be associated with CDC.

show abstract

“…They exhibit different molecular alterations, and therefore a differential response to therapies. The most frequent subtypes are clear cell RCC which comprises 80%, 6 papillary (10%–15%), 7 chromophobe (5%), 8 and collecting duct (1%) 9 . Localized RCC is effectively treated by surgical resection; meanwhile, metastatic RCC (mRCC) is treated with systemic therapies.…”

Section: Introductionmentioning

confidence: 99%

“…The most frequent subtypes are clear cell RCC which comprises 80%, 6 papillary (10%-15%), 7 chromophobe (5%), 8 and collecting duct (1%). 9 Localized RCC is effectively treated by surgical resection; meanwhile, metastatic RCC (mRCC) is treated with systemic therapies. However, this neoplasia is resistant to conventional chemotherapy and radiotherapy, and current strategies are only palliative.…”

Section: Introductionmentioning

confidence: 99%

Redox‐sensitive signaling pathways in renal cell carcinoma

et al. 2021

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is one of the most lethal urological cancers, highly resistant to chemo and radiotherapy. Obesity and smoking are the best-known risk factors of RCC, both related to oxidative stress presence, suggesting a significant role in RCC development and maintenance. Surgical resection is the treatment of choice for localized RCC; however, this neoplasia is hardly diagnosable at its initial stages, occurring commonly in late phases and even when metastasis is already present. Systemic therapies are the option against RCC in these more advanced stages, such as cytokine therapy or a combination of tyrosine kinase inhibitors with immunotherapies; nevertheless, these strategies are still insufficient. A field poorly analyzed in this neoplasia is the status of cell

show abstract

Genomic profiling of collecting duct renal carcinoma

Cited by 4 publications

References 8 publications

RNA Sequencing of Collecting Duct Renal Cell Carcinoma Suggests an Interaction between miRNA and Target Genes and a Predominance of Deregulated Solute Carrier Genes

Redox‐sensitive signaling pathways in renal cell carcinoma

Contact Info

Product

Resources

About